|
PARP Inhibition as Ovarian Cancer Maintenance Therapy: Improving Patient Outcomes as a Multidisciplinary Team
Ovarian cancer (OC) is often diagnosed at an advanced stage and has generally poor survival ratesĀ¬"even after aggressive surgical management and chemotherapy. Without maintenance therapy, approximately 70% of patients relapse within 3 years of treatment. Recent clinical trials of polyadenosine diphosphate-ribose polymerase (PARP) inhibitors have demonstrated substantial efficacy as maintenance therapy for OC patients. Additionally, clinical evidence suggests that daily monitoring of pati... |